Tredje AP fonden increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,939 shares of the pharmaceutical company’s stock after acquiring an additional 9,930 shares during the period. Tredje AP fonden’s holdings in Vertex Pharmaceuticals were worth $13,395,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Korea Investment CORP grew its holdings in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock valued at $104,000 after acquiring an additional 658 shares in the last quarter. Guardian Life Insurance Co. of America grew its holdings in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after acquiring an additional 6 shares in the last quarter. Dupont Capital Management Corp bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $186,000. State of Alaska Department of Revenue bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $197,000. Finally, Sterling Global Strategies LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at approximately $200,000. 92.88% of the stock is owned by institutional investors.

In related news, SVP Paul M. Silva sold 2,577 shares of the stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $133.36, for a total value of $343,668.72. Following the sale, the senior vice president now directly owns 22,648 shares of the company’s stock, valued at approximately $3,020,337.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Leiden sold 216,624 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.96, for a total transaction of $34,867,799.04. Following the completion of the sale, the chief executive officer now directly owns 400,266 shares in the company, valued at $64,426,815.36. The disclosure for this sale can be found here. Insiders sold a total of 526,092 shares of company stock worth $84,101,702 over the last three months. 1.80% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Stake Boosted by Tredje AP fonden” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/07/vertex-pharmaceuticals-incorporated-vrtx-stake-boosted-by-tredje-ap-fonden.html.

Vertex Pharmaceuticals Incorporated (VRTX) traded down 0.61% during midday trading on Thursday, reaching $156.12. The company’s stock had a trading volume of 247,488 shares. The firm has a 50 day moving average price of $155.53 and a 200 day moving average price of $124.16. The firm has a market cap of $39.36 billion, a P/E ratio of 149.97 and a beta of 1.75. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. During the same period in the prior year, the company posted $0.24 EPS. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.

Several research firms have recently issued reports on VRTX. J P Morgan Chase & Co set a $184.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Oppenheimer Holdings, Inc. upped their target price on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Maxim Group set a $195.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Morgan Stanley reissued an “overweight” rating and set a $190.00 price objective (up from $153.00) on shares of Vertex Pharmaceuticals in a report on Saturday, July 22nd. Finally, Vetr lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective for the company. in a report on Monday, July 24th. Six investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $162.88.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.